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MYB (the human ortholog of c-myb) is expressed in a high pro-
portion of human breast tumors, and that expression correlates
strongly with estrogen receptor (ER) positivity. This may reflect the
fact thatMYB is a target of estrogen/ER signaling. Because in many
cases MYB expression appears to be regulated by transcriptional
attenuation or pausing in the first intron, we first investigated
whether this mechanism was involved in estrogen/ER modulation
of MYB. We found that this was the case and that estrogen acted
directly to relieve attenuation due to sequences within the first
intron, specifically, a region potentially capable of forming a
stem–loop structure in the transcript and an adjacent poly(dT)
tract. Secondly, given the involvement of MYB in hematopoietic
and colon tumors, we also asked whether MYB was required for
the proliferation of breast cancer cells. We found that proliferation
of ER but not ER breast cancer cell lines was inhibited whenMYB
expression was suppressed by using either antisense oligonucle-
otides or RNA interference. Our results show that MYB is an
effector of estrogen/ER signaling and provide demonstration of a
functional role of MYB in breast cancer.
antisense  cell cycle  proliferation  short hairpin RNA 
transcriptional attenuation
TheMYB oncogene encodes a transcription factor (Myb) thathas predominantly been associated with normal and leuke-
mic hematopoiesis. This association is based on its pattern of
expression (1, 2), the consequences of reduced or ablated
expression (3, 4), and the ability of activated or overexpressed
forms of Myb to contribute to leukemogenesis in several species
(reviewed in ref. 5). It has also been known for some time that
MYB is expressed at relatively high levels in at least two epithelial
tumors: colon (6) and breast cancer (7). In the former, data are
accumulating that indicate a functional role in carcinogenesis;
these include a correlation of expression level with poor prog-
nosis (8) and the presence of mutations that are likely to
dysregulate MYB expression in colon carcinomas (9, 10).
Guerin et al. (7) first reported that MYB was expressed in a
high proportion of human breast tumors and that expression
correlated strongly with estrogen receptor (ER) positivity. This
has been borne out by other studies that have examined cell lines
(e.g., ref. 11) and by analysis of data from studies of large
numbers of tumors by using microarray expression profiling [see
supporting information (SI) Fig. 6].
Moreover, a basis for the correlation is suggested by reports
showing that estrogen/ER signaling directly modulates MYB
expression (11, 12). Interestingly, one study (11) suggests that
ER signaling enhances MYB expression at a level other than
transcriptional initiation. In many cell types, MYB expression
appears to be regulated by transcriptional attenuation or pausing
in the first intron (13, 14), and our work has shown that this
involves a region potentially capable of forming a stem–loop
(SL) structure in the transcript and an adjacent poly(dT) region
(9, 10). Intriguingly, this motif is frequently mutated in colon
carcinomas but not in breast cancer (10), suggesting that another
mechanism is responsible for overcoming attenuation in breast
cancer cells. Also in contrast to colon cancer, there are essen-
tially no data that address a functional role for MYB in breast
carcinogenesis, with the exception of a correlation between
BRCA1 mutation and MYB amplification in 30% of BRCA1
mutant tumors (15).
Here, we report that estrogen/ER acts directly to relieve
transcriptional attenuation due to sequences within the first
intron, specifically, the SL–poly(dT) motif. Moreover, given the
involvement ofMYB in hematopoietic and colon tumors and that
MYB is a direct ER target, we asked whetherMYB was required
for the proliferation and/or survival of ER  breast cancer cells.
By using antisense (AS) oligonucleotides and RNA interference
to blockMYB expression, we found that this was indeed the case,
providing functional evidence of a role forMYB in breast cancer.
Results
Transcriptional Regulation of MYB Expression by Estrogen. To con-
firmMYB regulation by estrogen, we used the well characterized
ER breast cancer cell line MCF-7. Fig. 1A shows that -estra-
diol treatment resulted in a rapid 4- to 5-fold increase in
expression determined by quantitative RT-PCR and that induc-
tion of MYB did not require protein synthesis because it was
insensitive to treatment of the cells with cycloheximide, which is
in agreement with other studies (12). The kinetics of induction
were very similar to those of another, well documented ER
target, pS2 (Fig. 1A). We also confirmed (i) a concomitant
increase in the rate of proliferation of MCF-7 cells (data not
shown; see also Fig. 3); (ii) that ER breast tumor cells (MDA-
MB-468) expressed 10- to 40-fold lessMYB mRNA than MCF-7
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cells; and (iii) that this did not increase in response to -estradiol
(SI Fig. 7).
In view of studies showing that MYB expression is frequently
regulated by transcriptional pausing within intron 1 (9, 13, 14),
we next performed nuclear run-on assays by using labeled RNA
from ER (MCF-7) and ER (MDA-MB-231) breast cancer
cells. Fig. 1C shows that in MDA-MB-231 cells and in untreated
MCF-7 cells, transcription could be detected in all cases by
probes (p1 and p2; Fig. 1B) spanning exon 1 and the first 1 kb
of intron 1. However, virtually no transcription proceeding
through the first intron past the SL–poly(dT) motif to exons 2
and 3 could be detected. In contrast, in -estradiol-treated
MCF-7 cells, the level of transcripts hybridizing to probes
encompassing the 3 portion of intron 1, and exons 2 and 3
(probes p3–p5; Fig. 1B), increased strikingly (13-, 63-, and
109-fold, respectively; see SI Fig. 8 for quantitation). These data
imply that estrogen/ER signaling relieved a block of transcrip-
tional elongation in intron 1 and that this block occurred within
the vicinity of the SL–poly(dT) motif.
To characterize the requirements for transcriptional attenu-
ation and its relief by -estradiol, we next used a chloramphen-
icol acetyl transferase (CAT) reporter construct containing the
MYB promoter, exon 1, and roughly the first half of intron 1,
including the SL–poly(dT) motif (Fig. 2A) (10). This reporter
was transfected into MCF-7 cells, which were cultured in the
absence or presence of -estradiol. Fig. 2B shows that CAT
activity was increased 3.5-fold in the presence of estrogen,
indicating that all of the elements required for -estradiol
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Fig. 1. Estrogen induces increased MYB mRNA levels and overcomes transcriptional attenuation. (A) MCF-7 cells were treated with 10 nM -estradiol for the
indicated times in the presence or absence of 10 g/ml cycloheximide, and the levels of MYB and pS2 mRNA were quantitated by quantitative RT-PCR. (B)
Schematic representation of part of the human MYB gene illustrating the location of the SL and poly(dT) motifs (SL-dT) in the first intron and the location of
probes (p1–p5) used in nuclear run-on transcription assays. (C) Transcriptional activity, measured by nuclear run-on assays, in the 5 region of the MYB gene was
compared before (T 0) and after (T 24) exposure of MCF-7 and MDA-MB-231 cells to 10 nM -estradiol for 12 h. The 32P-UTP-labeled RNA transcripts were
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Fig. 2. Reporter assays reveal that -estradiol relieves the suppression of transcription due to the SL–poly(dT) motif. (A) Schematic illustration of the MYB
reporter construct in which CAT transcription is driven by the humanMYBpromoter through exon 1 and part of intron 1 (WT). Also shown are deletion constructs
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responsiveness are contained within theMYB sequences present
in the reporter construct. Next, to examine the roles of the SL
and poly(dT) motifs, these were deleted from the reporter
construct either singly or together. Each of these constructs
showed the same level of activity in the absence and presence of
-estradiol, and, critically, this level of activity was very similar
to that seen in the parental construct in the presence of
-estradiol (Fig. 2B). Thus, -estradiol appeared to relieve a
block to expression that normally requires both the SL and
poly(dT) motifs.
Requirement for MYB for Estrogen-Dependent Proliferation. The
observations described above indicate that MYB expression in the
ER breast cancer cell line MCF-7 is regulated by -estradiol/ER
signaling, leading to the relief of transcriptional attenuation within
intron 1. However, what are the implications of this for ER breast
cancer? To address this question, we treated MCF-7 cells with a
previously validated MYB AS oligonucleotide (16). Fig. 3A shows
that the MYB AS oligonucleotide, but not a scrambled control
(SCR) oligonucleotide, strongly inhibited -estradiol-dependent
proliferation of these cells. Specific knockdown of Myb by the AS
oligonucleotidewas shown byWestern blotting (Fig. 3B), which also
showed that, as expected, Myb was induced by -estradiol and that
the SCR oligonucleotide had no effect on Myb levels. Quantitative
RT-PCR confirmed specific knockdown of c-MYB, but not B-MYB,
mRNA (SI Fig. 9A). We noted that growth of AS-treated cells was
slower than that of cells not treated with -estradiol (Fig. 3A),
probably because of further suppression of the low levels of MYB
present in such cells. AS oligonucleotide treatment had no effect on
cell viability (data not shown), indicating that the effect was on
proliferation per se.
To confirm the generality of this observation, we treated
several other breast cancer cell lines with the MYB AS oligonu-
cleotide. As with MCF-7 cells, the proliferation of ER T47D
and ZR-75-1 cells in the presence of -estradiol was strongly
inhibited by the AS, but not the SCR oligonucleotides; however,
there was no effect on the proliferation of the ER MDA-MB-
231 or MDA-MB-468 cell lines under any of the conditions (Fig.
3C). Knockdown of MYB was confirmed by quantitative RT-
PCR in each case (SI Fig. 9B). Thus, it appears that MYB is
necessary for the proliferation of ER but not ER breast cancer
cell lines, which is consistent with the relative expression ofMYB
in these two classes. Because it is possible that inhibition by AS
oligonucleotides was influenced by nonspecific or off-target
effects, we also used a second approach, RNA interference, to
stably knockdown Myb expression. An inducible short hairpin
(sh)RNA-expressing lentiviral vector, pLVTSH, was used to
stably transduce MCF-7 cells. Briefly, this vector (Fig. 4A and
data not shown) expresses shRNA under the control of a
Tet-repressor-regulated H1 promoter and also encodes the Tet
repressor itself, as well as GFP. Thus, shRNA is expressed in
transduced cells only in the presence of tetracycline analogs. Fig.
4 B and C shows that proliferation of MCF-7 cells transduced
with a MYB shRNA vector was inhibited only in the presence of
doxycycline (Dox). Cells transduced with a control shRNA
vector or empty pLVTSH showed no reduction in growth under
either condition. Specific knockdown of Myb was confirmed by
Western blotting (Fig. 4D).
Inhibition of proliferation could reflect either cell death or a
block in cell cycle progression. The former was ruled out by
studies on cell viability and apoptosis induction (data not
shown). DNA content analysis (Fig. 5) revealed that induction of
MYB shRNA resulted in a block of progression from the G1/S
and G2/M phases, consistent with previous reports in other cell
types (e.g., ref. 17).
Discussion
Estrogen Regulation of MYB Expression. Although previous studies
have shown that MYB is a target of estrogen/ER signaling, the
precise mechanism involved has not been determined. The data
of Gudas et al. (11) suggest that regulation is not at the level of
transcriptional initiation according to nuclear run-on studies
that used a large cDNA fragment as a probe. However, the use
of such a probe would not necessarily reveal an attenuation
mechanism such as that reported for MYB in other cell systems,
whereby transcriptional elongation through the first intron is
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regulated to allow or block the production of full-length MYB
transcripts (9, 13, 14). The present study has shown that estro-
gen/ER signaling acts to relieve this block to transcriptional
elongation within the first intron. Thus, transcriptional attenu-
ation of MYB in breast cancer cells appears similar to that
described in other cell types, such as hematopoietic cells (13, 14)
and colon carcinoma (9, 10). Attenuation appears to occur
within a region between 1.4 kbp and 2.2 kbp from the start of
intron 1 which includes the SL–poly(dT) motif, and indeed our
nuclear run-on and reporter studies support the notion that this
motif represents the site of transcriptional blockage.
A potential artifact has been reported in nuclear run-on
studies on transcription of theMYC gene, whereby transcription
can appear to pause within, at most, a few hundred base pairs of
the promoter because of release of stalled RNA polymerase
complexes (18). However it is very unlikely that such an artifact
can account for our results, because, as also discussed by Hugo
et al. (10), (i) run-on experiments indicated that MYB transcrip-
tion was blocked in most cell types	1 kbp from the transcription
start site, and (ii) the SL and poly(dT) sequences also affected
transcription of a reporter construct (i.e., in studies not involving
nuclear run-on assays).
The precise mechanism by which elongation of MYB tran-
scripts is blocked by the SL–poly(dT) motif and how this block
is overcome has not been resolved, although the involvement of
NF-B family members has been suggested (19). Our finding that
the well studied estrogen-/ER-signaling system canmodulate this
process may shed some light on this issue. Because MYB
induction by -estradiol was direct and the elements required
were present in the reporter construct, it seemed likely that ER
would bind directly to those sequences. In fact, Carroll et al. (20)
have carried out a global analysis of ER-binding sites in MCF-7
cells and have found that ER does indeed bind to several regions
in and around the MYB gene, including a site within a 600-bp
region, present within our reporter construct, immediately up-
stream of the SL–poly(dT) motif (see http://research.dfci.har-
vard.edu/brownlab/datasets/index.php). We have confirmed this
observation by chromatin immunoprecipitation, which showed
-estradiol-induced binding of ER to a region close to the
SL–poly(dT) motif (SI Fig. 10). Inspection of this region re-
vealed two potential ER-binding sites. However, mutation of
these motifs failed to affect the -estradiol responsiveness of the
reporter construct (data not shown), implying that ER either
binds to a noncanonical sequence or that it interacts via another
transcription factor bound within this region. Given the location
of the ER-binding site near the presumptive attenuation region,
it is intriguing that the cyclin T1 subunit of the positive tran-
scription elongation factor b complex, which is known to pro-
mote transcription elongation (reviewed in ref. 21), has recently
- Dox
Myb
-+ -+ -+ -+
Parental MYB SCR Vector
0 1 2 3 4 5 6 7 8
0
2
4
6
8
10
12
14
16
Day
C
el
l N
u
m
b
er
 (
x 
10
,0
00
)
Day
0 1 2 3 4 5 6 7 8
0
2
4
6
8
10
12
14
16
C
el
l N
u
m
b
er
 (
x 
10
,0
00
)
+ Dox
Parental
MYB
SCR
Vector
Parental
MYB
SCR
Vector
LTR H1 TetO GFPTRexEF1α IRES SIN LTR
β-tubulin
A
B C
D
Fig. 4. Knockdown ofMYB by inducible shRNA decreases MCF-7 proliferation and Myb protein expression. (A) Schematic representation of the lentiviral vector
pLVTSH showing the following key elements (left to right): LTR, H1 promoter, Tet operator, shRNA template, EF1 promoter, Tet repressor, internal ribosome
entry site, GFP, self-inactivating LTR. (B and C) Parental MCF-7 cells or cells stably transduced with pLVTSH were grown in 10 nM -estradiol in the absence or
presence of Dox over 7 days. Neither the empty vector (Vector) nor a vector expressing a SCR affected proliferation, but the MYB shRNA vector inhibited
proliferation when cells were grown in the presence of Dox. (D) Western blot analysis showing the decreased expression of Myb in only the MYB shRNA
vector-transduced cells after treatment with Dox for 24 h. The membrane was also probed for -tubulin as a loading control.
 -
Parental MYB shRNA SCR shRNA Vector only
S G0/G1 G2/M
 +
0
20
30
10
40
50
60
70
80
Dox
P
er
ce
nt
ag
e
 +  + -  -  - +
Fig. 5. Knockdown ofMYBwith shRNA blocks cell cycle progression from the
G1/S phase in MCF-7 cells. The cell lines used in the studies illustrated in Fig. 4
were grown in the presence of -estradiol with or without Dox, as indicated,
for 72 h. They were then harvested for cell cycle distribution analysis by
propidium iodide staining and flow cytometry; percentages of cells in G0/G1,
S, and G2/M are shown for each treatment group.
Drabsch et al. PNAS  August 21, 2007  vol. 104  no. 34  13765
M
ED
IC
A
L
SC
IE
N
CE
S
been reported to interact directly with the ER (22). Moreover
this factor is an important mediator of relief of the transactiva-
tion-responsive-region-mediated block to elongation of HIV
RNA by HIV Tat (reviewed in ref. 23); interestingly, the
transactivation-responsive region is known to form a SL struc-
ture similar to that predicted for the SL element inMYB. It may
be useful to explore the involvement of positive transcription
elongation factor b components in the action of -estradiol on
MYB expression.
Requirement for MYB in ER Breast Cancer. To the best of our
knowledge, this report is the first to demonstrate a functional
role forMYB in breast cancer. We have shown that inhibition of
MYB expression severely impairs the proliferation of ER, but
not ER, breast cancer cell lines. Thus it is likely that the
requirement of ER tumor cells for MYB, and the regulation of
MYB by estrogen/ER signaling together underlie the strong
correlation between ER and MYB expression in primary breast
tumors (see Introduction). The relationship between MYB and
ER is also consistent with preliminary data indicating expression
of c-myb in normal, ERmurine mammary ductal epithelial cells
(data not shown). Together, these observations suggest thatMYB
is an important, and possibly essential, effector of estrogen
action in breast cancer.
Our findings raise a number of important questions. First,
what are the MYB target genes that are important for breast
cancer cell proliferation? Candidates among knownMYB targets
include MYC (24, 25) and CCNA1 (26), although other regula-
tors of these genes have been identified in breast cancer (e.g., ref.
27). Indeed, MYC is itself a direct target of ER signaling (28);
therefore, it would seem unlikely that inhibition of MYB exerts
its effects via MYC. Because MYB shRNA blocked cell cycle
progression at G1/S, other regulators active at this point in the
cell cycle would be logical candidates for further study. Second,
is MYB expression required for the initiation or progression of
mammary tumors, and, third, can enforced MYB expression
contribute to mammary tumorigenesis? The only reported sug-
gestion of the latter is from the amplification and overexpression
ofMYB in a subset of BRCA1-mutant tumors, and very rarely in
sporadic tumors (15). The generation of mammary-specific
transgenic and gene-targeted mice may help to clarify these
issues. Fourth, is there any potential therapeutic benefit in
targeting MYB in breast cancer? Given the availability of effec-
tive drugs that target estrogen/ER signaling, it would seem
unlikely that targetingMYB, which, in principle, is more difficult,
would be a practical first-line therapy. However, resistance to
antiestrogens such as tamoxifen is a significant problem; there-
fore, targeting ER effectors like MYB may be beneficial in such
cases. Moreover, tamoxifen also induces MYB (ref. 29 and data
not shown); therefore, it is possible that antiestrogens and
potential anti-MYB therapies (reviewed in ref. 30) would be
effective in combination.
Materials and Methods
Cell Culture. MDA-MB-231, MDA-MB-468, ZR-75-1, and T47D
cells were grown routinely in DMEM, 10% FCS, and penicillin–
streptomycin–L-glutamine (all from GIBCO/BRL, Grand Is-
land, NY). MCF-7 cells were grown routinely in the same
medium supplemented with 1 mM sodium pyruvate/0.1 mM
nonessential amino acids/10 g/ml insulin (Sigma, St. Louis,
MO). All cells were grown as a monolayer in 95% air/5% CO2.
For estrogen deprivation, cells were grown in the samemedia but
containing phenol-red-free DMEM and charcoal-stripped FCS
for 72 h. Cell proliferation was determined by cell counting by
using a Z1 Coulter counter (Beckman Coulter, Sydney, Austra-
lia). Cells were plated in 24-well plates at an initial concentration
of 5 
 104 cells per well in 0.5 ml of phenol-red-free media
overnight and then grown further in the presence or absence of
10 nM 17--estradiol (Sigma). Where indicated, cells were
exposed to 10g/ml cycloheximide (Sigma) for 30min before the
addition of media with or without 10 nM 17--estradiol.
Quantitative RT-PCR. Total RNA was prepared by using a RNeasy
MiniKit (Qiagen, Valencia, CA) according to the instructions of
the manufacturer. One microgram of total RNA was reverse
transcribed in a total of 20 l by using SuperScript III (Invitro-
gen, Carlsbad, CA). The resulting cDNA was then diluted to a
total volume of 100 l with sterile H2O. Each real-time PCR
consisted of 1 l of diluted reverse transcriptase product, iQ
SYBR Green Supermix (Bio-Rad, Hercules, CA), and 50 nM
forward and reverse primers (see below). Reactions were carried
out on a RotorGene 3000 (Corbett Research, Sydney, Australia)
at 95°C for 10 min, followed by 40 cycles of 95°C for 20 s, 56°C
for 20 s, and 72°C for 30 s. Fluorescence measurements analyzed
by using the RotorGene 3000 software. The fold-change expres-
sion of each gene was calculated by using theCTmethod, with
cyclophilin A as an internal control. Primers used for real-time
PCRwere: c-MYB forward, 5-GCCAAT TATCTCCCGAAT
CGA-3; c-MYB reverse, 5-ACC AAC GTT TCG GAC CGT
A-3; B-MYB forward, 5-GCC ACT TCC CTAACCGCA c-3;
B-MYB reverse, 5-ccc TTG ACA AGG TCT GGA TTC A-3;
cyclophilin A forward, 5-GGC AAA TGC TGG ACC CAA
CAC AAA-3; cyclophilin A reverse, 5-CTA GGC ATG GGA
GGG AAC AAG GAA-3.
Nuclear Run-On Transcription Analysis. MCF-7 and MDA-MB-231
were grown in the presence or absence of 10 nM 17--estradiol
for 24 h before the preparation of nuclei, labeling with 32P--
UTP, and RNA extraction, all of which was carried out as
described previously (9, 10). Probes p1 (pIE2), p4 (pIBg3), p5
(pIBg2–5), MYC and GAPDH have been described previously
(9). Two additional probes for use in nuclear run on, p2 and p3
(see Fig. 1B), were generated with PCR by using Pfu polymerase
(Invitrogen) and 50 nM p2 forward primer 5-ATC GAG GAG
AAA GAA TTC GAA GAG GGA GAG GAG GAG GA-3
and reverse primer 5-AGC TAG CAG ACA GGA TCC AAG
GAA AGG CGA ATG GAT TT-3 or p3 forward primer
5-AGC TGT GAG AAA GAA TTC TTG CAC ATC TTT
GCC TCT G-3 and reverse primer 5-ATC TAT GAG AAA
GCG GCC GCG GAA CTC CTT GGA AAG ACC-3, respec-
tively. The products were digested with EcoRI and BamHI or
EcoRI and NotI, respectively, and cloned into pBluescript KS
(Fermentas, Hanover,MD) for the preparation of cRNAprobes,
which were used for hybridization to labeled nuclear RNA (9,
10). The filters were imaged by using a Storm PhosphorImager
(Molecular Dynamics, Sunnyvale, CA), and the relative intensity
of the radioactive bands was measured by using ImageQuant 5.2
(Molecular Dynamics) and normalized to the GAPDH probe.
Reporter Assays. The CAT reporter constructs containing the
human c-MYB promoter, exon 1, and intron 1 sequences have
been described previously (10). MCF-7 cells were transiently
transfected with 900 ng of CAT reporter construct plus 100 ng
of a -actin-promoter-driven luciferase expression vector (a gift
fromC. Popa, University of Queensland, Queensland, Australia)
by using Lipofectamine 2000 (Invitrogen) according to the
instructions of the manufacturer. After transfection, the cells
were cultured with or without 10 nM 17--estradiol for 12 h
before harvesting. CAT expression was assayed with a CAT
ELISA kit (Roche, Indianapolis, IN) according to the specifi-
cations of the supplier. CAT activity was normalized with respect
to luciferase expression, which was determined by using LucLite
(PerkinElmer, Waltham, MA) according to the protocol of the
manufacturer.
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AS Oligonucleotides. c-MYB AS (5-acagaccaacgtttcggaccgtatt-
tctgt-3) and SCR phosphorothioate oligonucleotides (5-
ctttcgaatgtgacatttcgacacgccagt-3) were manufactured (Univer-
sity of Pennsylvania, Philadelphia) as published (16). Cells were
plated in 24-well plates at an initial concentration of 5
 104 cells
per well overnight and transfected with AS oligonucleotides as
described (31). Cell proliferation was determined as described
above; experiments were conducted in triplicate and repeated at
least twice. Cells were harvested for protein or RNA 24 h after
initial transfection.
Western Blotting.Western blot analysis was conducted essentially
as described previously (32). Briefly, extracts prepared in SDS
loading buffer were resolved in SDS/10% PAGE gels and
transferred to PVDF membranes. These were incubated over-
night in the presence of anti-c-Myb antibody 1.1 (33) and were
developed by using ECL Western blotting substrates (Pierce
Biotechnology, Rockford, IL).
Myb Knockdown by RNA Interference. The tetracycline-inducible
lentiviral shRNA vector pLVTSH is outlined briefly here. Vectors
used encoded a MYB shRNA 5-GAACCUCUUACAAUUU-
GCAGAAACACUUUCAUGAGAAGUGUUUCUGCAUUGU-
GUAAGAGGUUCUU-3 (with the bold sequences corresponding
to sense and AS c-MYB mRNA, respectively) and a SCR shRNA
5-AUAAGAAUGUCCAUCAGUUACGCCAUAUUCAU-
GAGAUAUGGCGUAACUGAUGGACAUUCUUAUUU-3.
Lentivirus was generated by cotransfection of HEK293T cells with
packaging plasmids essentially as described by Barry et al. (34) by
using Lipofectamine 2000 (Invitrogen) according to the instruc-
tions of the manufacturer. The supernatant was collected after 48 h
and filtered through a 0.45-m filter before being used to transduce
MCF-7 cells. MCF-7 cells were FACS sorted based on expression
of pLVTSH-encoded GFP. Proliferation was assayed in triplicate
cultures as described above in medium containing 10 nM 17--
estradiol and/or 5 g/ml Dox (Sigma, Sydney, Australia). A sample
of each culture was collected after 24 h to determine knockdown
efficiency by Western blotting.
Cell Cycle Analysis. Cells were harvested, washed twice with
ice-cold PBS, and fixed in 70% ethanol at 20°C for at least 30
min. The fixed cells were then washed twice with ice-cold PBS
and stained with 50 g/ml propidium iodide in the presence of
100 g/ml RNase A for 30 min. Cell cycle distribution was
analyzed by using FACS Calibur (Becton Dickinson, San Jose,
CA), and the resultant data were analyzed by using CellQuest
software (Becton Dickinson).
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